Antibacterial Activity of Moxifloxacin (Bay 12-8039) against Aerobic Clinical Isolates, and Provisional Criteria for Disk Susceptibility Tests
| ISSN: |
1435-4373
|
|---|---|
| Source: |
Springer Online Journal Archives 1860-2000
|
| Topics: |
Medicine
|
| Notes: |
Abstract Moxifloxacin (Bay 12–8039), ciprofloxacin, and levofloxacin were compared in vitro against 1074 clinical isolates gathered from different medical centers throughout North America during the winter months of 1997. Moxifloxacin E tests and broth microdilution tests gave comparable results. Moxifloxacin was particularly potent against respiratory pathogens such as Haemophilus influenzae and Streptococcus pneumoniae. Ciprofloxacin was the most potent study drug against the family of Enterobacteriaceae and Pseudomonas spp. For tests of 5 μg moxifloxacin disks, zone size criteria of ≤17 mm for resistant (MIC ≥8 μg/ml) and ≥21 mm for susceptible (MIC ≤2 μg/ml) are provisionally proposed for use while clinical trials are under way.
|
| Type of Medium: |
Electronic Resource
|
| URL: |
| _version_ | 1798296205869973505 |
|---|---|
| autor | Barry, A. L. Fuchs, P. C. Brown, S. D. |
| autorsonst | Barry, A. L. Fuchs, P. C. Brown, S. D. |
| book_url | http://dx.doi.org/10.1007/s100960050284 |
| datenlieferant | nat_lic_papers |
| hauptsatz | hsatz_simple |
| identnr | NLM206294603 |
| issn | 1435-4373 |
| journal_name | European journal of clinical microbiology & infectious diseases |
| materialart | 1 |
| notes | Abstract Moxifloxacin (Bay 12–8039), ciprofloxacin, and levofloxacin were compared in vitro against 1074 clinical isolates gathered from different medical centers throughout North America during the winter months of 1997. Moxifloxacin E tests and broth microdilution tests gave comparable results. Moxifloxacin was particularly potent against respiratory pathogens such as Haemophilus influenzae and Streptococcus pneumoniae. Ciprofloxacin was the most potent study drug against the family of Enterobacteriaceae and Pseudomonas spp. For tests of 5 μg moxifloxacin disks, zone size criteria of ≤17 mm for resistant (MIC ≥8 μg/ml) and ≥21 mm for susceptible (MIC ≤2 μg/ml) are provisionally proposed for use while clinical trials are under way. |
| package_name | Springer |
| publikationsjahr_anzeige | 1999 |
| publikationsjahr_facette | 1999 |
| publikationsjahr_intervall | 8004:1995-1999 |
| publikationsjahr_sort | 1999 |
| publisher | Springer |
| reference | 18 (1999), S. 305-309 |
| search_space | articles |
| shingle_author_1 | Barry, A. L. Fuchs, P. C. Brown, S. D. |
| shingle_author_2 | Barry, A. L. Fuchs, P. C. Brown, S. D. |
| shingle_author_3 | Barry, A. L. Fuchs, P. C. Brown, S. D. |
| shingle_author_4 | Barry, A. L. Fuchs, P. C. Brown, S. D. |
| shingle_catch_all_1 | Barry, A. L. Fuchs, P. C. Brown, S. D. Antibacterial Activity of Moxifloxacin (Bay 12-8039) against Aerobic Clinical Isolates, and Provisional Criteria for Disk Susceptibility Tests Abstract Moxifloxacin (Bay 12–8039), ciprofloxacin, and levofloxacin were compared in vitro against 1074 clinical isolates gathered from different medical centers throughout North America during the winter months of 1997. Moxifloxacin E tests and broth microdilution tests gave comparable results. Moxifloxacin was particularly potent against respiratory pathogens such as Haemophilus influenzae and Streptococcus pneumoniae. Ciprofloxacin was the most potent study drug against the family of Enterobacteriaceae and Pseudomonas spp. For tests of 5 μg moxifloxacin disks, zone size criteria of ≤17 mm for resistant (MIC ≥8 μg/ml) and ≥21 mm for susceptible (MIC ≤2 μg/ml) are provisionally proposed for use while clinical trials are under way. 1435-4373 14354373 Springer |
| shingle_catch_all_2 | Barry, A. L. Fuchs, P. C. Brown, S. D. Antibacterial Activity of Moxifloxacin (Bay 12-8039) against Aerobic Clinical Isolates, and Provisional Criteria for Disk Susceptibility Tests Abstract Moxifloxacin (Bay 12–8039), ciprofloxacin, and levofloxacin were compared in vitro against 1074 clinical isolates gathered from different medical centers throughout North America during the winter months of 1997. Moxifloxacin E tests and broth microdilution tests gave comparable results. Moxifloxacin was particularly potent against respiratory pathogens such as Haemophilus influenzae and Streptococcus pneumoniae. Ciprofloxacin was the most potent study drug against the family of Enterobacteriaceae and Pseudomonas spp. For tests of 5 μg moxifloxacin disks, zone size criteria of ≤17 mm for resistant (MIC ≥8 μg/ml) and ≥21 mm for susceptible (MIC ≤2 μg/ml) are provisionally proposed for use while clinical trials are under way. 1435-4373 14354373 Springer |
| shingle_catch_all_3 | Barry, A. L. Fuchs, P. C. Brown, S. D. Antibacterial Activity of Moxifloxacin (Bay 12-8039) against Aerobic Clinical Isolates, and Provisional Criteria for Disk Susceptibility Tests Abstract Moxifloxacin (Bay 12–8039), ciprofloxacin, and levofloxacin were compared in vitro against 1074 clinical isolates gathered from different medical centers throughout North America during the winter months of 1997. Moxifloxacin E tests and broth microdilution tests gave comparable results. Moxifloxacin was particularly potent against respiratory pathogens such as Haemophilus influenzae and Streptococcus pneumoniae. Ciprofloxacin was the most potent study drug against the family of Enterobacteriaceae and Pseudomonas spp. For tests of 5 μg moxifloxacin disks, zone size criteria of ≤17 mm for resistant (MIC ≥8 μg/ml) and ≥21 mm for susceptible (MIC ≤2 μg/ml) are provisionally proposed for use while clinical trials are under way. 1435-4373 14354373 Springer |
| shingle_catch_all_4 | Barry, A. L. Fuchs, P. C. Brown, S. D. Antibacterial Activity of Moxifloxacin (Bay 12-8039) against Aerobic Clinical Isolates, and Provisional Criteria for Disk Susceptibility Tests Abstract Moxifloxacin (Bay 12–8039), ciprofloxacin, and levofloxacin were compared in vitro against 1074 clinical isolates gathered from different medical centers throughout North America during the winter months of 1997. Moxifloxacin E tests and broth microdilution tests gave comparable results. Moxifloxacin was particularly potent against respiratory pathogens such as Haemophilus influenzae and Streptococcus pneumoniae. Ciprofloxacin was the most potent study drug against the family of Enterobacteriaceae and Pseudomonas spp. For tests of 5 μg moxifloxacin disks, zone size criteria of ≤17 mm for resistant (MIC ≥8 μg/ml) and ≥21 mm for susceptible (MIC ≤2 μg/ml) are provisionally proposed for use while clinical trials are under way. 1435-4373 14354373 Springer |
| shingle_title_1 | Antibacterial Activity of Moxifloxacin (Bay 12-8039) against Aerobic Clinical Isolates, and Provisional Criteria for Disk Susceptibility Tests |
| shingle_title_2 | Antibacterial Activity of Moxifloxacin (Bay 12-8039) against Aerobic Clinical Isolates, and Provisional Criteria for Disk Susceptibility Tests |
| shingle_title_3 | Antibacterial Activity of Moxifloxacin (Bay 12-8039) against Aerobic Clinical Isolates, and Provisional Criteria for Disk Susceptibility Tests |
| shingle_title_4 | Antibacterial Activity of Moxifloxacin (Bay 12-8039) against Aerobic Clinical Isolates, and Provisional Criteria for Disk Susceptibility Tests |
| sigel_instance_filter | dkfz geomar wilbert ipn albert fhp |
| source_archive | Springer Online Journal Archives 1860-2000 |
| timestamp | 2024-05-06T09:48:23.985Z |
| titel | Antibacterial Activity of Moxifloxacin (Bay 12-8039) against Aerobic Clinical Isolates, and Provisional Criteria for Disk Susceptibility Tests |
| titel_suche | Antibacterial Activity of Moxifloxacin (Bay 12-8039) against Aerobic Clinical Isolates, and Provisional Criteria for Disk Susceptibility Tests |
| topic | WW-YZ |
| uid | nat_lic_papers_NLM206294603 |